AstraZeneca to present scientific abstracts from its cardiovascular and metabolic disease portfolio at European Society of Cardiology (ESC) Congress 2015 in London

LONDON, 31-8-2015 — /EuropaWire/ — Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.

Presentation of the data, including sub-analyses of the BRILINTA® PEGASUS-TIMI 54 study, coincides with updates to the ESC guidelines on treatment of Non-ST Segment Elevation Myocardial Infarction patients, which will be presented at the congress on Sunday, 30 August. The updated guidelines will provide insight into long term dual antiplatelet therapy for patients with a history of heart attack.

The PEGASUS-TIMI 54 study sub-analyses will provide further understanding of the types of patients most likely to benefit from long-term treatment with BRILINTA. The data will also provide insight into the relationship between the time from a patient’s last treatment with P2Y12antiplatelet therapy and their risk of a subsequent heart attack, stroke or cardiovascular death as well as the effect of BRILINTA in this setting.

Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “It is encouraging to see guideline updates recognise the continuing risk for patients more than one year after their heart attack and consider how this risk can be managed. We are looking forward to the presentation of the PEGASUS-TIMI 54 sub-analyses during the ESC Congress 2015 and to continuing the debate about the long-term use of dual antiplatelet therapy for these patients.”

In March 2015, based on the results of the PEGASUS-TIMI 54 study1, the US Food and Drug Administration (FDA) granted Priority Review for BRILINTA for the prevention of atherothrombotic events in patients who have previously experienced a heart attack.

Additional sub-analyses of the PEGASUS-TIMI 54 study also being presented at the ESC Congress 2015 include research into the relationship between renal function and risk of ischaemic and bleeding events, evaluated in a subset of high-risk patients with reduced renal function, and a gender comparison sub-analysis, assessing the relative safety and efficacy of ticagrelor in women versus men.

Other data highlights at the ESC Congress 2015 include:

• Data from the APOLLO real-world evidence study, exploring the impact of associated risk factors (such as age ≥65 years, diabetes, history of >1 prior myocardial infarction or renal disease) on the likelihood of recurrent cardiovascular events [abstract P2467], as well as long-term national healthcare costs post-heart attack [abstract 3662], will be featured as poster presentations on Sunday 30 August and Monday 31 August.

• Data from the ATLANTIC-H24 analysis, exploring the effect of pre-hospital versus
in-hospital administration of ticagrelor during the first 24 hours post-procedure, specifically among patients who underwent percutaneous coronary intervention (PCI), will feature on Monday 31 August, as part of the Clinical Trial Update II – Antiplatelet therapy session [abstract 3914].

• Two additional sub-analyses from ATLANTIC, exploring the study results according to gender [abstract P551] and within the French sub-population [abstract P556] will also be featured as poster presentations.

• Data from the SUPPORT study demonstrating the impact of a new interactive smartphone application on improving patient adherence and quality of life [abstract 6649] will be explored during a rapid fire abstract session on Wednesday 2 September.

• A VOYAGER meta-analysis examining the role of statin therapy, such as CRESTOR®(rosuvastatin) [poster P6465], in risk of atherosclerotic cardiovascular disease over a 10 year period will be presented in a poster session on Tuesday 1 September.

ASTRAZENECA ABSTRACTS TO BE FEATURED AT THE ESC CONGRESS 2015

Abstract #, Title and Author
Time (BST) / Session
BRILINTA abstracts
Abstract P551
Worse short-term outcome for women with STEMI. Insights from the ATLANTIC study
Swahn E, et al
Saturday 29 August
11:00 – 16:00
Poster session 1: Infarction acute phase STEMI II
Abstract P556
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of the ATLANTIC study
Cayla G, et al
Saturday 29 August
11:00 – 16:00
Poster session 1: Infarction acute phase STEMI III
Abstract P1115
Dual anti-thrombotic effects of ticagrelor on Arterial Thrombosis: an anti-platelet agent with anti-coagulant properties
Reiner MF, et al
Sunday 30 August
Moderated poster presentation 10:34 – 10:42
Session: Clinical impact and modulation of endothelial (dys)function
Abstract P2463
High event rate in patients with acute coronary syndromes and atrial fibrillation: Results from the prospective EPICOR Registry
Zeymer U, et al
Sunday 30 August
14:00 – 18:00
Poster session 3: STEMI I
Abstract 3032
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial
Magnani G, et al
Monday 31 August
Oral presentation 09:24 – 09:41
Session: Antithrombotic drugs – An ongoing research
Abstract P3317
The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: Insights from the PEGASUS-TIMI 54 trial
O’Donoghue M, et al
Monday 31 August
10:00 – 11:00
Best posters session 4
Abstract P3318
Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial infarction – the PEGASUS-TIMI 54 platelet function substudy
Storey R, et al
Monday 31 August
10:00 – 11:00
Best posters session 4
Abstract 3914
Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: The ATLANTIC-H24 analysis
Montalescot G, et al
Monday 31 August
Rapid fire abstract 14:15 – 14:30
Session: Clinical Trial Update II – Antiplatelet therapy
Abstract 3918
Ischemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal
Bonaca MP, et al
Monday 31 August
Oral presentation 15:15 – 15:30
Session: Clinical Trial Update II – Antiplatelet therapy
ACS abstracts
Abstract P172
Biomarker-based prediction model for recurrent ischemic events in revascularized patients with acute coronary syndromes
Lindholm D, et al
Saturday 29 August
Moderated poster presentation 12:38 – 12:47
Session: Post infarction period
Abstract P2467
Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data on distribution and impact of combination of risk factors in a real-life setting
Jernberg T, et al
Sunday 30 August
14:00 – 18:00
Poster session 3: STEMI I
Abstract 3662
Long-term healthcare costs after myocardial infarction in a clinical practice setting in Sweden; results from a contemporary nationwide registry study
Janzon M, et al
Monday 31 August
08:30 – 12:30
Poster session 4: Improvement of medical care in cardiovascular patients: social and economic issues
Abstract 3030
Effect of Time to interventional treatment on NSTE-ACS Outcomes in PLATO
Pollack C, et al
Monday 31 August
Oral presentation 08:50 – 09:07
Session: Antithrombotic drugs – An ongoing research
Abstract 3031
Treatment and long-term results of acute coronary syndrome (ACS) in patients on chronic oral anticoagulants (OAC): data from the EPICOR (NCT01171404) study
Stepinska J, et al
Monday 31 August
Oral presentation 09:07 – 09:24
Session: Antithrombotic drugs – An ongoing research
Abstract P3319
Differences in dual antiplatelet treatment for acute coronary syndrome patients undergoing PCI or not: a Danish nationwide population-based cohort study
Gislason G, et al
Monday 31 August
10:00 – 11:00
Best posters session 4
Abstract P5340
Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with stable coronary artery disease
Biener M, et al
Tuesday 1 September
08:30 – 12:30
Poster session 6: Coronary artery disease and comorbidities I
Abstract 4972
Treatment pattern of dual antiplatelet therapy in 104,012 patients with acute coronary syndrome; a Swedish nationwide population based cohort study
Angeras O, et al
Tuesday 1 September
Rapid fire abstract 08:39 – 08:48
Session: Flash news on antithrombotics
Abstract 4975
Balancing the risk of ischaemic and bleeding events in ACS
Ducrocq G, et al
Tuesday 1 September
Rapid fire abstract 08:57 – 09:06
Session: Flash news on antithrombotics
Abstract 6649
Effects of interactive patient support with a smartphone app on drug adherence and lifestyle changes in myocardial infarction patients
Varenhorst C, et al
Wednesday 2 September
Rapid fire abstract 08:57 09:06
Session: Cardiovascular prevention: what works for whom?
Abstract 6654
Health outcomes and platelet-aggregation inhibition after acute myocardial infarction in clinical practice. Findings from the PIPER study
Esposti LD, et al
Wednesday 2 September
Rapid fire abstract 09:42 – 09:51
Session: Cardiovascular prevention: what works for whom?
CRESTOR abstracts
Abstract P6465
Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a VOYAGER meta-analysis
Karlson B, et al
Tuesday 1 September
14:00 – 18:00
Poster session 7: Surveillance of risk factors and interventions
Abstract P6551
YKL-40 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)
Kanwal AF, et al
Tuesday 1 September
14:00 – 18:00
Poster session 7: Prognosis II

NOTES TO EDITORS

1 Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.

About BRILINTA®

BRILINTA is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). BRILINTA works by inhibiting platelet activation.

BRILINTA (90mg) is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis.

BRILINTA is a registered trademark of the AstraZeneca group.

About the PEGASUS TIMI-54 study

PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome – Thrombolysis In Myocardial Infarction Study Group) is one of AstraZeneca’s largest ever outcomes trials with more than 21,000 patients from over 1,100 sites in 31 countries in Europe, the Americas, Africa and Australia/Asia. It was conducted in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group from Brigham and Women’s Hospital (Boston, MA, USA).

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:www.astrazeneca.com

CONTACTS

Media Enquiries

Name Region Phone Number
Esra Erkal-Paler UK/Global +44 20 7604 8030
Vanessa Rhodes UK/Global +44 20 7604 8037
Ayesha Bharmal UK/Global +44 20 7604 8034
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US + 1 302 885 6351

Investor Enquiries

UK

Name Area Phone Number Mobile Phone Number
Thomas Kudsk Larsen +44 20 7604 8199 +44 7818 524185
Eugenia Litz RIA +44 20 7604 8233 +44 7884 735627
Nick Stone CVMD +44 17 6326 3994 +44 7717 618834
Karl Hård Oncology +44 20 7604 8123 +44 7789 654364
Craig Marks ING +44 20 7604 8591 +44 7881 615764
Christer Gruvris +44 20 7604 8126 +44 7827 836825

US

Name Area Phone Number Mobile Phone Number
Dial / Toll-Free +1 301 398 3251 +1 866 381 7277

Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and Metabolic Disease, ING – Infection, Neuroscience and Gastrointestinal

Comments are closed.